Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
1(8%)
Results Posted
100%(7 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_4
8
67%
Ph not_applicable
2
17%
Ph phase_1
2
17%

Phase Distribution

2

Early Stage

0

Mid Stage

8

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 4Post-market surveillance
8(66.7%)
N/ANon-phased studies
2(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(7)
Terminated(2)
Other(1)

Detailed Status

Completed7
Terminated2
unknown1
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
77.8%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (16.7%)
Phase 48 (66.7%)
N/A2 (16.7%)

Trials by Status

unknown18%
not_yet_recruiting18%
completed758%
terminated217%
recruiting18%

Recent Activity

1 active trials
Showing 5 of 12
completedphase_4

Revealing Protective Immunity to Influenza Using Systems Immunology

NCT06501963
not_yet_recruitingphase_4

Intranasal LAIV Mucosal Immunity Examination

NCT07093281
recruitingphase_4

The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study

NCT07240922
completednot_applicable

Nasal and Systemic Immune Responses to Nasal Influenza Vaccine

NCT04110366
unknownphase_1

The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

NCT05056519
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06501963Phase 4

Revealing Protective Immunity to Influenza Using Systems Immunology

Completed
NCT07093281Phase 4

Intranasal LAIV Mucosal Immunity Examination

Not Yet Recruiting
NCT07240922Phase 4

The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study

Recruiting
NCT04110366Not Applicable

Nasal and Systemic Immune Responses to Nasal Influenza Vaccine

Completed
NCT05056519Phase 1

The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

Unknown
NCT01673425Not Applicable

Evaluating Immune Response to Seasonal FluMist in Healthy Adults

Terminated
NCT02549365Phase 4

Efficacy & Safety of Nasal Influenza Immunisation in Children

Completed
NCT03101462Phase 4

Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years

Completed
NCT01653015Phase 4

Live Versus Inactivated Influenza Vaccine Study in Hutterite Children

Completed
NCT01545349Phase 1

Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine

Completed
NCT01246999Phase 4

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Completed
NCT01194297Phase 4

Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants

Terminated

All 12 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
12